Tislelizumab
Monoclonal antibody targets PDCD1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | TEVIMBRA | — | 2025-04-22 – 2025-12-09 | fda.gov ↗ |
| Approved | US (FDA) | TEVIMBRA | — | 2024-03-13 | fda.gov ↗ |
| Approved | EU (EMA) | Tevimbra | — | 2023-09-15 | europa.eu ↗ |
Trials 628 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 07 trials | ||||||
| Phase 0 | NCT07389187 | Feb → Dec 2026 expected | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06866548 | Mar → Nov 2025 overdue | castration-resistant prostate carcinoma | Shanghai Changzheng Hospital | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06690476 | Oct 2024 → Jul 2026 overdue | esophageal squamous cell carcinoma | Peking University | Recruiting | No outcome recorded |
| Phase 0 | NCT06497010 | Aug 2024 → Jul 2026 overdue | neoplasm | The Affiliated Hospital Of Guizhou Medical University | Recruiting | No outcome recorded |
| Phase 0 | NCT06098898 | Nov 2023 → Nov 2024 | gastric cancer | Base Therapeutics (Shanghai) Co., Ltd. | Unknown | No outcome recorded |
| Phase 0 | NCT04906382 | Jul 2021 → Sep 2022 | Lynch syndrome, carcinosarcoma of the corpus uteri, endometrial clear cell adenocarcinoma, mismatch repair cancer syndrome | Floor Backes, MD | Terminated | No outcome recorded |
| Phase 0 | NCT05131698 | Mar 2021 → Dec 2023 | hepatocellular carcinoma | Cancer Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| Phase 160 trials | ||||||
| Phase 1 | NCT07692048 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07671339 | Jun 2026 → Jun 2028 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT07453875 | May 2026 → Nov 2027 expected | peritoneal carcinomatosis | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07414836 | Apr 2026 → Apr 2029 expected | neoplastic disease or syndrome | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT07348107 | Feb 2026 → Mar 2027 expected | pancreatic ductal adenocarcinoma | Daniel Breadner | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07353294 | Jan 2026 → Dec 2028 expected | metastatic malignant neoplasm in the lymph nodes, urothelial carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07059299 | Dec 2025 → Aug 2027 expected | esophageal adenocarcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting | No outcome recorded |
| Phase 1 | NCT07377045 | Oct 2025 → Mar 2029 expected | pancreatic ductal adenocarcinoma | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
| Phase 1 | NCT07317609 | Jul 2025 → Sep 2027 expected | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06916494 | May 2025 → Jan 2026 overdue | urinary bladder cancer | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT06868732 | Apr 2025 → Jun 2028 expected | non-small cell lung carcinoma | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06541639 | Mar 2025 → Mar 2028 expected | cancer | Peking University | Recruiting | No outcome recorded |
| Phase 1 | NCT06848465 | Feb 2025 → Aug 2026 overdue | metastasis from malignant tumor of colon | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Recruiting | No outcome recorded |
| Phase 1 | NCT06741982 | Dec 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06585488 | Dec 2024 → Apr 2026 | colorectal cancer, esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer +3 | BeOne Medicines | Terminated | No outcome recorded |
| Phase 1 | NCT06540066 | Sep 2024 → Jan 2026 | cancer of unknown primary site, metastatic malignant neoplasm | BeiGene | Terminated | No outcome recorded |
| Phase 1 | NCT06494189 | Jul 2024 → Apr 2025 | head and neck cancer | West China Hospital | Completed | No outcome recorded |
| Phase 1 | NCT06427941 | Jul 2024 → May 2028 expected | gastric cancer, hepatocellular carcinoma, non-small cell squamous lung carcinoma, yolk sac tumor | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06487858 | Jul 2024 → Apr 2026 | cancer | BeOne Medicines | Terminated | No outcome recorded |
| Phase 1 | NCT06422520 | Jul 2024 → May 2026 | neoplasm | BeOne Medicines | Completed | No outcome recorded |
| Phase 1 | NCT06463444 | Jun 2024 → Jun 2025 | hepatocellular carcinoma | Chen Xiaoping | Unknown | No outcome recorded |
| Phase 1 | NCT06349837 | Apr 2024 → Mar 2028 expected | cancer | Sichuan University | Recruiting | No outcome recorded |
| Phase 1 | NCT06233942 | Apr 2024 → Sep 2027 expected | neoplasm | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT06344156 | Apr 2024 → Apr 2026 overdue | pancreatic ductal adenocarcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 1 | NCT05644626 | Mar 2024 → Mar 2025 | cancer | BeiGene | Withdrawn | No outcome recorded |
| Phase 1 | NCT06091943 | Nov 2023 → Jul 2025 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05981703 | Sep 2023 → Sep 2027 expected | neoplastic disease or syndrome | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05935098 | Aug 2023 → Jan 2026 | metastatic neoplasm, neoplasm | BeiGene | Terminated | No outcome recorded |
| Phase 1 | NCT05984342 | Aug 2023 → Jun 2025 overdue | esophageal squamous cell carcinoma | Affiliated Cancer Hospital of Shantou University Medical College | Recruiting | No outcome recorded |
| Phase 1 | NCT05904496 | Jul 2023 → Aug 2025 | cancer | BeiGene | Terminated | No outcome recorded |
| Phase 1 | NCT05984602 | Jul 2023 → Sep 2025 overdue | malignant pancreatic neoplasm | NYU Langone Health | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05789069 | May 2023 → Dec 2026 expected | colorectal cancer, gastric cancer, melanoma, non-small cell lung carcinoma +1 | HiFiBiO Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05526924 | Mar 2023 → Jan 2028 expected | head and neck squamous cell carcinoma, pharynx cancer | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT05675462 | Mar 2023 → Dec 2025 | hepatocellular carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT05768932 | Dec 2022 → Dec 2026 expected | acute myeloid leukemia, gastric cancer, triple-negative breast carcinoma | SillaJen, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05659628 | Dec 2022 → Dec 2024 overdue | diffuse large B-cell lymphoma | Ningbo No. 1 Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT05508100 | Sep 2022 → Apr 2024 | neoplasm | Immune-Onc Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05533892 | Sep 2022 → Aug 2024 | hepatocellular carcinoma | Wan-Guang Zhang | Unknown | No outcome recorded |
| Phase 1 | NCT05494762 | Aug 2022 → Feb 2025 | cancer | BeiGene | Terminated | No outcome recorded |
| Phase 1 | NCT05273814 | Aug 2022 → Aug 2023 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05441046 | Jun 2022 → Jun 2024 | cancer | Changchun GeneScience Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05303844 | Apr 2022 → Mar 2025 | refractory malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 1 | NCT05303090 | Mar 2022 → Apr 2024 | pancreatic ductal adenocarcinoma | Fudan University | Completed | No outcome recorded |
| Phase 1 | NCT05238883 | Mar 2022 → Dec 2026 expected | cervical cancer, gastric cancer, head and neck squamous cell carcinoma, melanoma +5 | HiFiBiO Therapeutics | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05185531 | Mar 2022 → Dec 2024 | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 1 | NCT05167071 | Dec 2021 → Sep 2025 overdue | cancer, neuroendocrine neoplasm | Harbour BioMed (Guangzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05008861 | Sep 2021 → Dec 2022 | non-small cell lung carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05013268 | Sep 2021 → Jun 2022 | cervical squamous cell carcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT04649385 | Mar 2021 → Oct 2025 | neoplasm | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT04294160 | Jul 2020 → Sep 2024 | colorectal cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT04381741 | Jun 2020 → Sep 2023 | diffuse large B-cell lymphoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 1 | NCT04261439 | Feb 2020 → Dec 2023 | melanoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 1 | NCT04215978 | Jan 2020 → Jan 2025 | head and neck squamous cell carcinoma, nasopharyngeal carcinoma, non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT04047862 | Aug 2019 → Aug 2024 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03666143 | Nov 2018 → Jan 2023 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03732664 | Oct 2018 → Mar 2023 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Completed | No outcome recorded |
| Phase 1 | NCT03287427 | Aug 2018 → Dec 2022 | adenoid cystic carcinoma, colorectal cancer | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 1 | NCT02795182 | Jun 2016 → Dec 2020 | leukemia, lymphoma | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02660034 | Feb 2016 → Sep 2020 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02407990 | Jun 2015 → Aug 2020 | — | BeiGene | Completed | No outcome recorded |
| Phase 1/258 trials | ||||||
| Phase 1/2 | NCT07681297 | Aug 2026 → Aug 2028 expected | central nervous system disorder, triple-negative breast carcinoma | National University Hospital, Singapore | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07694765 | Jul 2026 → Dec 2028 expected | cancer | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07698587 | Jul 2026 → Dec 2029 expected | cancer | Suzhou Biomissile Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07468071 | Jun 2026 → Jun 2029 expected | — | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07477444 | Jun 2026 → Jun 2028 expected | gastroesophageal cancer | Universitaire Ziekenhuizen KU Leuven | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07502768 | Apr 2026 → Dec 2027 expected | extranodal nasal NK/T cell lymphoma, mature T-cell and NK-cell non-Hodgkin lymphoma | Rong Tao | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07244705 | Nov 2025 → Apr 2028 expected | colorectal cancer | Anbogen Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07190027 | Nov 2025 overdue | non-small cell lung carcinoma | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07025850 | Aug 2025 → Jan 2027 expected | colorectal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07010120 | Jun 2025 → May 2027 expected | head and neck squamous cell carcinoma | West China Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06966154 | May 2025 → May 2027 expected | T-cell and NK-cell neoplasm, extranodal nasal NK/T cell lymphoma | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06825494 | Apr 2025 → Mar 2026 overdue | neoplasm | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06499350 | Nov 2024 → Jul 2026 overdue | cancer | FindCure Biosciences (ZhongShan) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06586099 | Oct 2024 → Jun 2025 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06456138 | Jul 2024 → Jun 2026 overdue | non-small cell lung carcinoma, refractory malignant neoplasm | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06364956 | May 2024 → Jun 2026 overdue | urinary bladder cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06394791 | May → Dec 2024 | colorectal cancer | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05906524 | Apr 2024 → Apr 2025 | hepatocellular carcinoma | Shanghai Kanda Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT06266871 | Mar 2024 → Jun 2026 overdue | gastric cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07561060 | Jan 2024 → Dec 2027 expected | rectal cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05937438 | Sep 2023 → Sep 2025 overdue | carcinoma of esophagus | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05978102 | Aug 2023 → Jun 2027 expected | neoplasm | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05886439 | May 2023 → May 2027 expected | lung cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05982834 | May 2023 → May 2025 | carcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05746728 | Apr 2023 → Aug 2024 | triple-negative breast carcinoma | Huihua Xiong | Unknown | No outcome recorded |
| Phase 1/2 | NCT05651022 | Feb 2023 → Jun 2027 expected | colorectal cancer, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma +2 | Indaptus Therapeutics, Inc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05699811 | Feb 2023 → Dec 2025 overdue | — | Chinese PLA General Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05319639 | Feb 2023 → Oct 2024 overdue | gastric cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05675813 | Feb 2023 → Jul 2026 overdue | peripheral T-cell lymphoma, not otherwise specified | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05840835 | Feb 2023 → Jan 2024 | neoplasm | Immix Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05609370 | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05661955 | Jan 2023 → May 2025 overdue | melanoma, renal cell carcinoma, urothelial carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05581719 | Nov 2022 → Apr 2024 | peritoneal carcinomatosis | Enlivex Therapeutics RDO Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05505877 | Sep 2022 → Oct 2024 | neoplasm | Shanghai Gopherwood Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05842317 | Sep 2022 → Apr 2024 | hepatocellular carcinoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05431270 | Aug 2022 → Dec 2027 expected | non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Phanes Therapeutics | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05464433 | Jun 2022 → Apr 2025 overdue | mature T-cell and NK-cell non-Hodgkin lymphoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06303583 | Jun 2022 → Aug 2024 overdue | esophageal squamous cell carcinoma | Qiu Guoqin | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT05833984 | May 2022 → Feb 2024 | classic Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05394415 | May 2022 → Apr 2024 | esophageal squamous cell carcinoma | Jiangsu Cancer Institute & Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05267054 | Apr 2022 → Aug 2024 | diffuse large B-cell lymphoma | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT04577963 | Aug 2021 → Jun 2024 | colorectal cancer, endometrial cancer, triple-negative breast carcinoma | Hutchmed | Terminated | No outcome recorded |
| Phase 1/2 | NCT04922047 | Jun → Dec 2021 | urinary bladder neoplasm | RenJi Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT04796857 | Mar 2021 → Mar 2023 | ALK-positive anaplastic large cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, high grade B-cell lymphoma | Huiqiang Huang | Unknown | No outcome recorded |
| Phase 1/2 | NCT04963088 | Mar 2021 → Mar 2024 | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Completed | No outcome recorded |
| Phase 1/2 | NCT04579757 | Mar 2021 → Apr 2024 | colorectal cancer, gastric cancer, metastatic neoplasm, small cell lung carcinoma +2 | Hutchmed | Terminated | No outcome recorded |
| Phase 1/2 | NCT04699188 | Feb 2021 → Jan 2027 expected | colorectal carcinoma, non-small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04782804 | Jan 2021 → Dec 2023 | intrahepatic cholangiocarcinoma | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04652440 | Dec 2020 → Dec 2023 | hepatocellular carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04979663 | Dec 2020 → Jun 2022 | biliary tract cancer | Fudan University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05777707 | Oct 2020 → Dec 2023 | carcinoma of esophagus | Beijing Friendship Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT06022692 | Jun 2020 → May 2022 | digestive system neoplasm | Pengyuan Liu | Completed | No outcome recorded |
| Phase 1/2 | NCT04282018 | Apr 2020 → Aug 2024 | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT04276493 | Mar 2020 → Dec 2023 | breast cancer, gastric cancer, gastroesophageal cancer | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT03941873 | Feb 2019 → Mar 2023 | gastroesophageal junction adenocarcinoma, hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT03744468 | Nov 2018 → Feb 2025 | head and neck squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT03379259 | Nov 2017 → Sep 2020 | cancer | BeiGene | Terminated | No outcome recorded |
| Phase 1/2 | NCT04068519 | Dec 2016 → Dec 2018 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 2415 trials | ||||||
| Phase 2 | NCT07714447 | Nov 2026 → Feb 2029 expected | colorectal cancer | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07686926 | Aug 2026 → Jul 2028 expected | esophageal squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07300891 | Aug 2026 → Jan 2027 expected | refractory malignant neoplasm | Samsung Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07700667 | Jul 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07655661 | Jul 2026 → Jul 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ming Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07685704 | Jul 2026 → Jun 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Zhifeng Zhao, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07669415 | Jun 2026 → Dec 2027 expected | neoplasm | LaNova Medicines Limited | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07609667 | Jun 2026 → Jun 2028 expected | gastroesophageal junction adenocarcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07608978 | Jun 2026 → Dec 2028 expected | diffuse large B-cell lymphoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07584733 | May 2026 → Dec 2027 expected | renal pelvis/ureter urothelial carcinoma | RenJi Hospital | Not yet recruiting | No outcome recorded |
| Show all 415 trials opens the full record — a long page | ||||||
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07131319 | Apr 2025 → Oct 2028 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06563245 | Sep 2024 → Nov 2029 expected | classic Hodgkin lymphoma | Children's Cancer Group, China | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06443671 | Jun 2024 → Jun 2026 overdue | rectal cancer | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06312982 | Mar 2024 → Dec 2026 expected | rectal carcinoma | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05699655 | May 2023 → Mar 2025 overdue | — | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05409417 | Oct 2022 → Feb 2024 | metastasis from malignant tumor of colon | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT05325528 | Apr 2022 → Aug 2025 | — | Zhejiang University | Unknown | No outcome recorded |
| Phase 2/3 | NCT04973306 | Mar 2022 → Jul 2024 overdue | esophageal squamous cell carcinoma | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase 353 trials | ||||||
| Phase 3 | NCT07691515 | Jul 2026 → Jan 2030 expected | intrahepatic cholangiocarcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07475026 | May 2026 → Jan 2030 expected | hepatocellular carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06914011 | May 2026 → Jun 2031 expected | esophageal cancer | Asan Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07385703 | Apr 2026 → Oct 2028 expected | adenocarcinoma | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07402538 | Feb 2026 → Dec 2028 expected | oral cavity cancer, oropharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07315750 | Jan 2026 → Jun 2029 expected | gastric carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07132008 | Oct 2025 → Sep 2027 expected | colonic neoplasm | First Affiliated Hospital of Guangxi Medical University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06745908 | Oct 2025 → Sep 2028 expected | non-small cell lung carcinoma | ImmunityBio, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07043400 | Aug 2025 → Oct 2027 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 3 | NCT07132463 | Aug 2025 → Dec 2027 expected | rectum adenocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06841172 | Jul 2025 → Jul 2027 expected | hepatocellular carcinoma | Shandong Cancer Hospital and Institute | Recruiting | No outcome recorded |
| Phase 3 | NCT07068516 | Jul 2025 → Jun 2027 expected | gastric cancer | Xiangdong Cheng | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06957938 | Apr 2025 → May 2029 expected | hypopharyngeal carcinoma, laryngeal carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06332274 | Apr 2025 → Apr 2029 expected | colorectal cancer, lung cancer, malignant pancreatic neoplasm, soft tissue sarcoma | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT06939439 | Dec 2024 → Dec 2026 expected | gastric cancer | The First Affiliated Hospital with Nanjing Medical University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06734702 | Nov 2024 → Nov 2028 expected | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT06520683 | Nov 2024 → Nov 2027 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT07070622 | Nov 2024 → Dec 2027 expected | rectal cancer | West China Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06507371 | Jul 2024 → May 2026 overdue | rectal cancer | Sir Run Run Shaw Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06465446 | Jun 2024 → Jun 2026 overdue | classic Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06258811 | Feb 2024 → Dec 2026 expected | oral cavity squamous cell carcinoma | Lai-ping Zhong | Recruiting | No outcome recorded |
| Phase 3 | NCT05910970 | Feb 2024 → Dec 2025 | hepatocellular carcinoma | Guangxi Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT06031597 | Sep 2023 → Dec 2025 | non-small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT05823311 | Sep 2023 → Dec 2026 expected | cholangiocarcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 3 | NCT06017583 | Sep 2023 → Aug 2024 overdue | rectal neoplasm | Yong Zhang,MD | Recruiting | No outcome recorded |
| Phase 3 | NCT05791097 | Jul 2023 → Dec 2027 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT05564338 | Jun 2023 → Apr 2027 | hepatocellular carcinoma | BeiGene | Withdrawn | No outcome recorded |
| Phase 3 | NCT06441110 | Jun 2023 → Jun 2025 overdue | urinary bladder neoplasm | Fujian Medical University Union Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05582265 | Oct 2022 → Oct 2028 expected | head and neck squamous cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05211232 | Jun 2022 → Jun 2026 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05342792 | Apr 2022 → Jun 2027 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 3 | NCT05207709 | Mar 2022 → Mar 2026 | breast cancer | SOLTI Breast Cancer Research Group | Terminated | No outcome recorded |
| Phase 3 | NCT05346952 | Jan 2022 → Dec 2023 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05152147 | Dec 2021 → Jul 2026 overdue | esophageal adenocarcinoma, gastric neoplasm, gastroesophageal adenocarcinoma | Jazz Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04921358 | Jul 2021 → Dec 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04789434 | Jul 2021 → Jul 2023 | diffuse large B-cell lymphoma, disease related to transplantation | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04866017 | Jun 2021 → Oct 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04746924 | May 2021 → May 2025 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04799314 | Apr 2021 → Apr 2023 | diffuse large B-cell lymphoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04486391 | Dec 2020 → Oct 2025 | classic Hodgkin lymphoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04379635 | May 2020 → Aug 2023 overdue | non-small cell lung carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT04005716 | Jul 2019 → Apr 2023 | small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03957590 | Jun 2019 → Jan 2025 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03745222 | May → Jun 2019 | non-small cell lung carcinoma | Celgene Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT03924986 | Mar 2019 → Mar 2021 | nasopharyngeal carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03777657 | Dec 2018 → Feb 2023 | gastroesophageal adenocarcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03783442 | Dec 2018 → Feb 2022 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03594747 | Jul 2018 → Sep 2020 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03663205 | Jul 2018 → Jan 2020 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03430843 | Jan 2018 → Dec 2020 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03412773 | Dec 2017 → Jul 2022 | hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 3 | NCT03358875 | Nov 2017 → Jul 2021 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT07485920 | May 2026 → Dec 2028 expected | small cell lung carcinoma | The Affiliated Hospital of Qingdao University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06951841 | Apr 2025 → May 2026 overdue | small cell lung carcinoma | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06356675 | Jul 2024 → Jul 2028 expected | non-small cell lung carcinoma | The First Affiliated Hospital, Guangzhou University of Traditional Chinese Medicine | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06357598 | Jan → Dec 2024 | non-small cell lung carcinoma | The Affiliated Hospital of Qingdao University | Unknown | No outcome recorded |
| Phase 4 | NCT06003673 | Jul 2023 → Jul 2024 | hepatocellular carcinoma | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT05861635 | Feb 2023 → Feb 2025 | breast cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 4 | NCT05580354 | Oct 2022 → Oct 2024 | urinary bladder carcinoma | Ruijin Hospital | Unknown | No outcome recorded |
| Phase not applicable20 trials | ||||||
| — | NCT07535840 | May → Dec 2026 expected | hepatocellular carcinoma | Tongji Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07480382 | Apr 2026 → Dec 2027 expected | hepatocellular carcinoma | Hong Wu | Not yet recruiting | No outcome recorded |
| — | NCT07396090 | Jan → Oct 2026 expected | — | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| — | NCT07243691 | Dec 2025 → Nov 2027 expected | hepatocellular carcinoma | Sir Run Run Shaw Hospital | Recruiting | No outcome recorded |
| — | NCT07067450 | Jul 2025 → Dec 2026 expected | esophageal squamous cell carcinoma | Sichuan University | Not yet recruiting | No outcome recorded |
| — | NCT07068542 | Jul 2025 → Dec 2027 expected | differentiated thyroid carcinoma, poorly differentiated thyroid gland carcinoma | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| — | NCT06740370 | Dec 2024 → Dec 2025 overdue | hepatocellular carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06622031 | Oct 2024 → Dec 2026 expected | hepatocellular carcinoma, portal vein thrombosis | Sun Yat-sen University | Recruiting | No outcome recorded |
| — | NCT06363708 | Jun 2024 → Dec 2025 | endometrium neoplasm | Zhongnan Hospital | Unknown | No outcome recorded |
| — | NCT06199232 | Jan 2024 → Jun 2026 overdue | metastasis from malignant tumor of colon | Peking University | Active not recruiting | No outcome recorded |
| — | NCT05963087 | Aug 2023 → Feb 2025 | colorectal cancer | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| — | NCT06056115 | May 2023 → Apr 2025 overdue | lung adenocarcinoma | Hebei Medical University Fourth Hospital | Recruiting | No outcome recorded |
| — | NCT05811793 | Apr 2023 → Dec 2024 | glioblastoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| — | NCT05527808 | Aug 2022 → Jun 2025 | lung adenocarcinoma | Jun Liu | Unknown | No outcome recorded |
| — | NCT05546619 | Aug 2022 → Jul 2025 | hepatocellular carcinoma | Sulai Liu | Unknown | No outcome recorded |
| — | NCT05339581 | May 2022 → Dec 2023 | hepatocellular carcinoma, portal vein thrombosis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT05247996 | Mar → Dec 2022 | intrahepatic cholangiocarcinoma | The Central Hospital of Lishui City | Unknown | No outcome recorded |
| — | NCT05277675 | Nov 2021 → Nov 2022 | hepatocellular carcinoma | Southwest Hospital, China | Unknown | No outcome recorded |
| — | NCT05027100 | Sep 2021 → Dec 2022 | small cell lung carcinoma | Haibo Zhang | Unknown | No outcome recorded |
| — | NCT05058755 | Sep 2021 → Dec 2022 | extranodal nasal NK/T cell lymphoma | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Also used as a comparator or background therapy in 93 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06097962 Background | Jul 2023 → Jul 2026 overdue | non-small cell lung carcinoma | Base Therapeutics (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 19 trials | ||||||
| Phase 1 | NCT07565740 Background | May 2026 → May 2027 expected | oropharynx squamous cell carcinoma | West China Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT07077369 Background | Aug 2025 → Dec 2027 expected | hepatocellular carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07119996 Background | Aug 2025 → Feb 2026 overdue | bladder transitional cell carcinoma | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1 | NCT06896422 Background | Jun 2025 → Dec 2026 expected | non-small cell lung carcinoma | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 1 | NCT06969612 Background | May 2025 → May 2027 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT06596473 Background | Oct 2024 → Dec 2027 expected | cancer | BeOne Medicines | Recruiting | No outcome recorded |
| Phase 1 | NCT05798533 Background | Jan → Sep 2023 | cancer | BGI, China | Unknown | No outcome recorded |
| Phase 1 | NCT05547321 Background | Oct 2022 → Dec 2027 expected | — | Oncomatryx Biopharma S.L. | Recruiting | No outcome recorded |
| Phase 1 | NCT04387084 Background | Aug 2020 → Aug 2026 overdue | skin cancer | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT05982522 Background | Aug 2025 → Dec 2026 | neoplasm | InxMed (Shanghai) Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06871527 Background | Mar 2025 → Mar 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06471673 Background | May 2024 → Apr 2025 overdue | breast cancer | BriaCell Therapeutics Corporation | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06431243 Background | May 2024 → May 2026 overdue | neoplasm | Chengdu Zenitar Biomedical Technology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06030258 Background | Oct 2023 → Dec 2025 overdue | small cell lung carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06136910 Background | May 2023 → May 2024 | non-small cell lung carcinoma | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05632939 Background | Feb 2023 → Oct 2025 overdue | gastric cancer, gastroesophageal cancer | AskGene Pharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04813107 Comparator | Dec 2021 → Nov 2023 | urinary bladder carcinoma | Jiangsu Yahong Meditech Co., Ltd aka Asieris | Unknown | No outcome recorded |
| Phase 1/2 | NCT04666688 Background | Dec 2020 → Dec 2024 | colorectal cancer, head and neck cancer, malignant pancreatic neoplasm, metastatic malignant neoplasm +1 | PureTech | Completed | No outcome recorded |
| Phase 1/2 | NCT04425070 Background | Aug 2020 → Dec 2025 | mature T-cell and NK-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified | Antengene Corporation | Terminated | No outcome recorded |
| Phase 233 trials | ||||||
| Phase 2 | NCT07691645 Background | Sep 2026 → Aug 2029 expected | hepatocellular carcinoma | Xiang-Qian | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07469306 Comparator | Aug 2026 → Aug 2027 expected | — | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07678580 Background | Jul 2026 → Jan 2028 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07623642 Background | Jun 2026 → Jun 2028 expected | cervical cancer, cholangiocarcinoma, colorectal neoplasm, esophageal squamous cell carcinoma +7 | GV20 Therapeutics | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07609121 Background | Jun 2026 → May 2029 expected | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07557914 Background | Jun 2026 → Feb 2029 expected | diabetes mellitus, hepatocellular carcinoma | Haibo Shao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07569068 Comparator | Apr 2026 → Apr 2028 expected | gastroesophageal adenocarcinoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07463248 Background | Mar 2026 → Jan 2028 expected | hepatocellular carcinoma | Wang Xin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07331155 Comparator | Feb 2026 → Dec 2028 expected | — | Nanjing Leads Biolabs Co.,Ltd | Recruiting | No outcome recorded |
| Phase 2 | NCT07172412 Background | Nov 2025 → Dec 2027 expected | small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06897579 Comparator | Apr 2025 → Apr 2026 | small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT07058103 Background | Apr 2025 → Apr 2028 expected | angioimmunoblastic T-cell lymphoma | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06888037 Background | Mar 2025 → Mar 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06829355 Background | Feb → Dec 2025 overdue | colorectal cancer | Beijing Friendship Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06793228 Background | Jan 2025 → Jan 2027 expected | small cell lung carcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06703047 Comparator | Nov 2024 → Nov 2029 expected | esophageal squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06695013 Background | Nov 2024 → Nov 2026 expected | B-cell non-Hodgkin lymphoma | Ruijin Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06749886 Background | Nov 2024 → Nov 2026 expected | lung cancer | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05628610 Background | Sep 2024 → Sep 2026 expected | esophageal cancer | Fujian Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06509568 Comparator | Aug 2024 → Aug 2026 overdue | esophageal squamous cell carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06446726 Background | Jun 2024 → Jun 2025 overdue | esophageal squamous cell carcinoma | Sichuan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06157996 Background | Jun 2024 → Aug 2026 overdue | gastric cancer | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06403111 Background | Jun 2024 → Jun 2026 overdue | non-small cell lung carcinoma | Changzhou No.2 People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06010303 Background | Nov 2023 → May 2025 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT06084897 Background | Oct 2023 → Apr 2026 overdue | esophageal cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT06139419 Background | Jul 2023 → Aug 2026 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05900921 Background | Jul 2023 → Oct 2024 | non-small cell squamous lung carcinoma | Sichuan University | Unknown | No outcome recorded |
| Phase 2 | NCT05620498 Background | Sep 2022 → Jun 2023 | cholangiocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT05014815 Background | Nov 2021 → Sep 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05254899 Background | Oct 2021 → Sep 2022 | extranodal nasal NK/T cell lymphoma | Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT05582278 Background | Jan 2021 → Jan 2024 | hepatocellular carcinoma | Wen Li | Unknown | No outcome recorded |
| Phase 2 | NCT04562311 Background | Jan 2021 → Aug 2024 overdue | urinary bladder cancer | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04539444 Background | Aug 2020 → Sep 2022 | non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07554456 Background | Jun 2026 → Dec 2028 expected | esophageal squamous cell carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07662811 Comparator | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07662395 Comparator | May 2026 → Jan 2030 expected | — | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07251062 Comparator | Dec 2025 → Dec 2029 expected | esophageal squamous cell carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT06841679 Background | Aug 2025 → Sep 2030 expected | gastroesophageal adenocarcinoma | Beijing Biostar Pharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05809336 Background | May 2019 → Oct 2022 | neoplasm | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 326 trials | ||||||
| Phase 3 | NCT07715396 Comparator | Oct 2026 → Oct 2031 expected | non-small cell lung carcinoma | AIO-Studien-gGmbH | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07677293 Comparator | Jun 2026 → Dec 2028 expected | adenocarcinoma | Peking University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07672223 Comparator | Jun 2026 → Sep 2029 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07633873 Comparator | Jun 2026 → Sep 2027 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07416474 Comparator | Apr 2026 → Dec 2027 expected | non-small cell lung carcinoma | RemeGen Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07502300 Background | Apr 2026 → Dec 2029 expected | small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07373990 Comparator | Jan 2026 → Apr 2028 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07383116 Comparator | Jan 2026 → Apr 2028 expected | non-small cell lung carcinoma | Shanghai Huaota Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07328854 Background | Nov 2025 → Jun 2030 expected | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 3 | NCT07170995 Comparator | Oct 2025 → Dec 2030 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06364904 Background | Oct 2025 → Apr 2027 expected | urinary bladder cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07174908 Comparator | Sep 2025 → Sep 2028 expected | non-small cell lung carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06793917 Background | Jun 2025 → Apr 2028 expected | gastric cancer | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT06944496 Comparator | May 2025 → May 2028 expected | gastric carcinoma | RemeGen Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06704620 Background | Dec 2024 → Nov 2026 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06598527 Background | Oct 2024 → Jan 2027 expected | non-small cell lung carcinoma | Yang Hong | Recruiting | No outcome recorded |
| Phase 3 | NCT06416410 Comparator | Aug 2024 → Sep 2026 expected | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06383780 Comparator | May 2024 → May 2027 expected | nasopharyngeal carcinoma | XIANG YANQUN | Recruiting | No outcome recorded |
| Phase 3 | NCT06206733 Background | Jan 2024 → Dec 2026 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | AskGene Pharma, Inc. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06177301 Background | Dec 2023 → Dec 2026 expected | nasopharyngeal carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05990127 Comparator | Nov 2023 → Aug 2025 overdue | — | Akeso | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05840016 Comparator | Aug 2023 → Feb 2025 overdue | non-small cell squamous lung carcinoma | Akeso | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05919030 Background | Jul 2023 → Jul 2026 overdue | esophageal squamous cell carcinoma | Renmin Hospital of Wuhan University | Recruiting | No outcome recorded |
| Phase 3 | NCT05718167 Comparator | Feb 2023 → Oct 2024 | non-small cell squamous lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04170283 Background | Jan 2020 → Nov 2027 expected | B-cell neoplasm | BeiGene | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03967977 Comparator | May 2019 → Jun 2027 expected | urothelial carcinoma | BeiGene | Active not recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07567313 Comparator | Apr 2026 → Jan 2028 expected | squamous cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07320105 Background | Jan 2026 → Jan 2027 expected | non-small cell lung carcinoma | Fujian Cancer Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06761911 Comparator | Dec 2024 → Dec 2025 overdue | Hodgkins lymphoma | Xiuhua Sun | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05603065 Comparator | Oct 2022 → Oct 2023 | esophageal squamous cell carcinoma | First Affiliated Hospital Xi'an Jiaotong University | Unknown | No outcome recorded |
| Phase not applicable4 trials | ||||||
| — | NCT06607926 Background | Oct 2024 → Jun 2025 overdue | non-small cell lung carcinoma | Xuanwu Hospital, Beijing | Not yet recruiting | No outcome recorded |
| — | NCT06702566 Background | Jul 2024 → Jul 2026 overdue | acute leukemia, cancer | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| — | NCT05834413 Background | May 2023 → Jun 2027 expected | lung cancer | Shanghai University of Traditional Chinese Medicine | Recruiting | No outcome recorded |
| — | NCT07537985 Background | Jan 2020 → Aug 2025 | hepatocellular carcinoma | Sun Yat-sen University | Completed | No outcome recorded |
Press releases naming this drug 8 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-10 | Novartis Pharmaceuticals | Novartis announces tislelizumab demonstrated efficacy and tolerability in first-line advanced liver cancer in Phase III trial novartis.com ↗ |
| 2022-06-30 | Novartis Pharmaceuticals | New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy novartis.com ↗ |
| 2022-04-27 | Novartis Pharmaceuticals | Novartis tislelizumab plus chemotherapy significantly improved overall survival as first-line treatment for advanced esophageal cancer in Phase III study novartis.com ↗ |
| 2022-04-06 | Novartis Pharmaceuticals | Novartis announces anti-PD-1 tislelizumab accepted by EMA for regulatory review in esophageal and lung cancers novartis.com ↗ |
| 2021-09-13 | Novartis Pharmaceuticals | Novartis announces first FDA filing acceptance for anti-PD-1 antibody tislelizumab for people with esophageal cancer novartis.com ↗ |
| 2021-06-04 | Novartis Pharmaceuticals | Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy novartis.com ↗ |
| 2021-02-26 | Novartis Pharmaceuticals | Novartis strengthens Oncology pipeline with successful closing of tislelizumab in-licensing novartis.com ↗ |
| 2021-01-11 | Novartis Pharmaceuticals | Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene novartis.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 725 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tislelizumab | “Therefore, this study aims to conduct a prospective, single-arm, phase II clinical study, targeting HCC patients with high-risk recurrence factors, to evaluate whether...” NCT06467799 ↗717“PD-1 blockade (comprising tislelizumab <200 mg/cycle>, carrellimab <200 mg/cycle>, or toripalimab <240 mg/cycle>) once every 3 weeks for two years, or until intolerable...” NCT06472713 ↗ “This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with...” NCT07623642 ↗ “This study is a prospective, double-blind, multicenter, randomized controlled phase II clinical trial of tislelizumab combined with chemotherapy and all trans retinoic acid in...” NCT06703047 ↗ “Tislelizumab, an anti-programmed death protein-1 (PD-1) monoclonal antibody, was engineered to minimize binding to FcγR on macrophages to abrogate antibody-dependent...” NCT04672317 ↗ “Patients in the nCIT group will receive two cycles of TC chemotherapy combined with immunotherapy, specifically paclitaxel (albumin-bound) 100 mg/m² on days 1, 8, 15 or...” NCT06509568 ↗ “Combination phase Anti-PD1 monoclonal antibody: Choose one of the anti-PD-1 monoclonal antibody drugs reimbursed by medical insurance, toripalimab (240mg), camrelizumab...” NCT06259721 ↗ “All the enrolled patients receive 2 doses of inductive anti-PD-1 antibody (Tislelizumab 200mg) every two weeks, and then Involved-site radiotherapy (50±6-10 Gy) with concurrent...” NCT05149170 ↗ “A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line...” NCT05346952 ↗ “The enrolled patients received intravenous injections of PD-1 monoclonal antibody (Tislelizumab 200mg) on the 1 day before radiofrequency or microwave ablation treatment, and...” NCT04652440 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “Cetuximab β Injection: 500 mg/m² per dose (calculated based on body surface area), followed by 250 mg/m2, administered intravenously, once a week; Tislelizumab was administered...” NCT07714447 ↗ “Following this, a period of one to two weeks was to elapse before the initiation of Tislelizumab (200 mg), Docetaxel (75 mg/m²), and Cisplatin (75 mg/m²), on a three-week...” NCT07402538 ↗ “Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma...” PMID 35720312 ↗ Jun 2022 “Anti-PD-1 antibody (Tislelizumab) was administrated at 200 mg on day 1 every 3 weeks and selinexor doses and schedules ranged from 40 mg weekly for 2 weeks per 21-day cycle to...” PMID 37616529 ↗ Jan 2024 “Phase I and Extended Clinical Study of Safety, Tolerability, and Pharmacokinetics of Injectable Genakumab Alone and Combination With Tislelizumab in the Treatment of Advanced...” NCT05441046 ↗ “Fixed Delay Arm Delayed PD-1 + Chemo PD-1 inhibitor (e.g., Sintilimab/Keytruda/Tislelizumab/Camrelizumab/Toripalimab/Nivolumab/Atezolizumab/Sugemalimab) Immune checkpoint...” NCT07190027 ↗ “Three days after cryoablation, the patients receive intravenous infusion of Tislelizumab (200mg, with 100mL of normal saline) and Bevacizumab (dose 15mg/kg, with 100mL of...” NCT06530784 ↗ “Patients assigned to experimental arm would receive the maintenance treatment of immune checkpoint inhibitor (Tislelizumab or Camrelizumab) after postoperative radiotherapy for one year” NCT05937438 ↗ “After radiotherapy, two cycles of XELOX+ tislelizumab were given, with the specific doses of oxaliplatin 130mg/m2, d1, capecitabine 1000mg/m2, D1-14, q3w, and tislelizumab 200mg, q3w.” NCT07070622 ↗ “ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.” NCT05834413 ↗ “Potential options include Sintilimab, Tislelizumab, or other approved PD-1 antibody products indicated for the treatment of metastatic gastric or gastroesophageal adenocarcinoma.” NCT06468280 ↗ “Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study.” PMID 40889502 ↗ Aug 2025 “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel 260 mg/m², cisplatin 75 mg/m², and tislelizumab 200 mg, administered every 3 weeks.” NCT06734702 ↗ “T Cell Inflamed Gene Expression Profiling Score-guided Anti PD-1 Therapy (Tislelizumab Monotherapy) for Refractory Solid Cancer Patients Unexposed to Immunotherapy” NCT07300891 ↗ “Two to four cycles of tislelizumab at a dose of 200 mg every three weeks, along with a platinum-based chemotherapy doublet based on the result of ctDNA dynamics” NCT06977074 ↗ “Disitamab Vedotin (2mg/kg, q2w), Tislelizumab (2mg/kg, q2w) combined with low-dose capecitabine 0.5g bid chemotherapy and the COX2 inhibitor celecoxib 200mg bid” NCT05578287 ↗ “This intervention combines perioperative zanidatamab with chemotherapy and the PD-1 inhibitor tislelizumab for HER2-positive gastroesophageal adenocarcinoma” NCT07477444 ↗ “followed by Tislelizumab (200mg) with platinum-based doublet chemotherapy administered pre-operatively every 3 weeks for 3 cycles before surgical resection.” NCT06877299 ↗ “Participants without disease progression, grade ≥3 toxicities, and/or grade ≥2 pneumonitis after CCRT receive tislelizumab 200 mg (Q3W) for up to 12 months.” NCT06139419 ↗ “Toripalimab 240 mg on day 1, every 3 weeks, or Tislelizumab 200 mg on day 1, every 3 weeks, or Camrelizumab 200 mg on day 1, every 3 weeks, for 4-6 cycles.” NCT07528183 ↗ “TREND-02 - a Phase II Exploratory De-escalation Trial of Neoadjuvant Sacituzumab Govitecan Plus Tislelizumab (SG/I) in Early Triple-negative Breast Cancer” NCT07271992 ↗ “Pembrolizumab, 200mg, Q3W or Nivolumab, 3mg/kg, Q2W or Tislelizumab，200mg，Q3W or Camrelizumab，200mg，Q3W or Sintilimab，200mg，Q3W or Toripalimab，240mg，Q3W” NCT06170710 ↗ “Tislelizumab is an investigational, humanized, IgG4 monoclonal antibody with high affinity and binding specificity for programmed cell death-1 (PD-1)” PMID 32561638 ↗ Jun 2020 “Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)” NCT06740370 ↗ “maintenance therapy with Zanubrutinib plus Tislelizumab until disease progression, unacceptable toxicity, or completion of 1 year of maintenance” NCT07608978 ↗ “Tislelizumab：200 mg per dose, intravenous infusion over 30 minutes, every 3 weeks as a cycle for 17 cycles after concurrent chemoradiotherapy” NCT05342792 ↗ “Specific agent (e.g., Pembrolizumab, Durvalumab, Toripalimab, or Tislelizumab) may be chosen based on local availability and patient access.” NCT07282262 ↗ “If a PD-1 inhibitor is administered in combination, tislelizumab (200 mg), or pembrolizumab (200 mg), or nivolumab (360 mg), iv, day1, q3w.” NCT06841679 ↗ “PD-1 antibody (Tislelizumab) was performed simultaneously with concurrent chemoradiotherapy (Triprizumab 200mg，d1，every 3 weeks，2 cycles ).” NCT04821765 ↗ “Participants will receive either tislelizumab (200 mg, IV Q3W) or sintilimab (200 mg, IV Q3W) for a lead-in period of one to three cycles.” NCT06497010 ↗ “Tislelizumab will be administered every 4 weeks up to 6 cycles during induction phase if patients get CR or PR after induction phase.” NCT04796857 ↗ “Tislelizumab (3 cycles): 200mg i.v. q3w on day 1 of each cycle, and starting from the second week after the start of radiotherapy” NCT05507112 ↗ “a fixed 200 mg dose of a PD-1 inhibitor (Sintilimab, Tislelizumab, or Toripalimab) is administered via intra-arterial injection” NCT07504471 ↗ “intravenous administration of tislelizumab (an anti-PD-1 immune checkpoint inhibitor) was initiated within 3 hours post-HIPEC.” NCT07068178 ↗ “This study intends to conduct a study on the neoadjuvant treatment of tislelizumab, carboplatin, and albumin-bound paclitaxel.” NCT06130332 ↗ “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab, Nivolumab), 200mg/dose, iv drip, q3w.” NCT07537985 ↗ “Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer” NCT06136910 ↗ “Immunotherapy drugs can be Pembrolizumab /Penpulimab/ Camrelizumab/ Tislelizumab / Sintilimab/ sulgarizumab and so on” NCT06032052 ↗ “Tegafur (S-1) 80mg/100mg/120mg Q3W (discontinued at the third week) + tislelizumab 200 mg Q3W, treatment for 1 year.” NCT06354140 ↗ “Immunotherapy, with agents including but not limited to ramucirumab, pembrolizumab, camrelizumab, and tislelizumab.” NCT07691645 ↗ “Patients will receive salvage treatment of PD-1 inhibitor Tislelizumab combined with decitabine for four cycles” NCT05137886 ↗ “Tislelizumab: 200mg, iv, Q3W, 1year at most(including preoperative treatment medication, a total of 17 cycles).” NCT07089199 ↗ “PD-1: Nivolumab(360mg IV d1, Q3W）；Sintilimab(200mg IV d1, Q3W）；Tislelizumab(200mg IV d1, Q3W） can be selected;” NCT05721651 ↗ “PD-1 inhibitor (Sintilimab, Camrelizumab, Tislelizumab, Toripalimab, Pembrolizumab), 200mg/dose, iv drip, q3w.” NCT07501351 ↗ “PD-1 inhibitor includes pembrolizumab，Nivolumab，Sintilimab，tislelizumab，Triplimab，Camrelizumab, Serplulimab.” NCT06702566 ↗ “Subjects receive Tislelizumab 200mg intravenously (IV) once every 3 weeks (Q3W) until disease progression” NCT07174908 ↗ “PD-1 blockade (Sintilimab/Camrelizumab/Toripalimab/Tislelizumab), 200 mg, IV., every 3 weeks, 2-3 cycles.” NCT05777707 ↗ “Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks” NCT05640726 ↗ “Tislelizumab is the first- and second-line standard treatment for advanced ESCC with tolerable toxicity.” PMID 40001034 ↗ Feb 2025 “Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.” PMID 32540858 ↗ Jun 2020 “Optional types of immune checkpoint inhibitors include Sintilimab injection and Tislelizumab injection.” NCT05247996 ↗ “Nivolumab or Pembrolizumab or Tislelizumab or Serplulimab or Toripalimab or Sintilimab or Camrelizumab” NCT06084897 ↗ “Cohort B is for patients with advanced solid tumors treated with PM in combination with tislelizumab.” NCT06431243 ↗ “Tislelizumab (a PD-1 inhibitor): 200 mg, intravenous drip for 30-60 minutes before 24h of HAIC, q4w.” NCT06199232 ↗ “Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab” NCT05409417 ↗ “Pembrolizumab/Tislelizumab/Sintilimab/Camrelizumab, 200mg solution intravenously once daily, Q3W.” NCT06121700 ↗ “Participants will receive FMT combined with tislelizumab + pemetrexed + platinum-based treatment” NCT06403111 ↗ “Tislelizumab: 200 mg, administered intravenously on the first day of each treatment cycle.” NCT06003673 ↗ “HAIC (Irinotecan liposome plus 5-FU/LV ) combined with lenvatinib and Tislelizumab” NCT07646717 ↗ “Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.” NCT07125547 ↗ “Programmed cell death-1 (PD-1, Tislelizumab, BeiGene) prior to hepatic resection” NCT05185531 ↗ “Then the maintenance treatment phase with tislelizumab + lenvatinib is entered” NCT06202716 ↗ “Tislelizumab 200 mg , once every 3 weeks (Q3W), intravenous infusion (iv).” NCT07328854 ↗ “the anti-PD-1 antibody tislelizumab and SOX (oxaliplatin+S-1) chemotherapy” PMID 40953882 ↗ Sep 2025 “IN Type: Glofitamab + PD-1 inhibitor (e.g., Tislelizumab) + Lenalidomide” NCT07602322 ↗ “e.g. pembrolizumab, camrelizumab, sintilimab, tislelizumab, toripalimab” NCT06896422 ↗ “Patients were treated with one cycle of Tislelizumab 200 mg monotherapy” NCT06469060 ↗ “Tislelizumab in Combination With Chemotherapy(etoposide/cisplatin )” NCT06851819 ↗ “Tislelizumab: 400 mg intravenously on Day 1 of each 42-day cycle” NCT07507526 ↗ “Tislelizumab 200 mg, IV infusion, Q3W, maintenance for 2 years.” NCT07567313 ↗ “Tislelizumab is an approved PD-1 inhibitor for advanced NSCLC.” NCT07692048 ↗ “Tislelizumab 200mg will be given every 3 weeks for 12 cycles” NCT04870905 ↗ “Gemcitabine +capecitabine, tislelizumab, neoantigen vaccines” NCT06344156 ↗ “tislelizumab (intravenously, 200 mg on day 1 of every cycle)” NCT04819971 ↗ “tislelizumab 200 mg on day 1, q3w, for a total of 6 cycles” NCT07523737 ↗ “Immunotherapy: tislelizumab,the fixed dose of 200 mg IV.” NCT04562311 ↗ “three 21-day cycles tislelizumab (200 mg, iv.gtt, day8)” NCT04911517 ↗ “ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.” NCT06249750 ↗ “plus 200mg Tislelizumab every 3 weeks for 6 times” NCT04381741 ↗ “Tislelizumab (200mg intravenously every 3 weeks)” NCT06622031 ↗ “Tislelizumab: 200 mg IV on day 1, every 3 weeks” NCT07067268 ↗ “\- Tislelizumab 200 mg intravenously on day 1.” NCT07297030 ↗ “tislelizumab（an anti-PD-1 monoclonal antibody）” NCT05143099 ↗ “Drug: Tislelizumab Tislelizumab 200mg IV Q3W” NCT05019677 ↗ “Drug: Tislelizumab Tislelizumab 200mg IV Q3W” NCT05023109 ↗ “PD-1 antibody (Tislelizumab): 200mg d1 q3w” NCT06507371 ↗ “PD-1 antibody (Tislelizumab): 200mg d1 q3w” NCT05972655 ↗ “tislelizumab 200mg intravenously on day 6” NCT07000617 ↗ “2. Tislelizumab + Cisplatin + Paclitaxel” NCT07251062 ↗ “3 cycles of tislelizumab（200 mg D1 q3w）” NCT07339488 ↗ “Drug:BM230 Drug:Tislelizumab Injection” NCT07698587 ↗ “Tislelizumab (200 mg IV every 3 weeks)” NCT07458529 ↗ “Tislelizumab (immunotherapy) 200mg Q3W” NCT07231575 ↗ “PD-1 blockade (comprising tislelizumab” NCT07070479 ↗ “PD-1 antibody，Tislelizumab (BGB-A317)” NCT04815408 ↗ “Tislelizumab 200mg/3 weeks, iv, D1” NCT06888037 ↗ “Tislelizumab 200mg every 3 weeks” NCT06388031 ↗ “Sintilimab or Tislelizumab, Q3w” NCT07677293 ↗ “PD-1 inhibitor (Tislelizumab)” NCT06536959 ↗ “Tislelizumab (200mg on day 1)” NCT06835179 ↗ “Tislelizumab 200mg iv，d1，q3w” NCT06475755 ↗ “Tislelizumab, 200 mg, q3w” NCT06685887 ↗ “Tislelizumab injection” NCT05809336 ↗ “Tislelizumab Injection” NCT05699811 ↗ “Tislelizumab 200mg d1” NCT05254899 ↗ “Drug: Tislelizumab” NCT06695013 ↗ “Tislelizumab” NCT06379087 ↗ “Tislelizumab” NCT06134193 ↗ “Tislelizumab” NCT06031597 ↗ “tislelizumab” NCT06303583 ↗ “Tislelizumab” NCT05008861 ↗ |
| Known as | BGB A317 | “This is a Phase 2, single-arm, multicenter study, evaluating the anti-tumor efficacy of tumor-infiltrating lymphocyte (TIL) directed tislelizumab monotherapy (also known as...” NCT07300891 ↗19“Tirelizumab,has been approved for the failure treatment of platinum-containing chemotherapy with high PD-L1 expression included locally advanced or metastatic Urothelial...” NCT04562311 ↗ “Tislelizumab (T, BGB-A317) is a humanized IgG4 mAb with high affinity and specificity for programmed cell death protein 1 (PD1), showing a superior antitumor activity compared...” NCT05977673 ↗ “Tislelizumab (also known as BGB A317) is a humanized, immunoglobulin G4 (IgG4)-variant monoclonal antibody against programmed cell death protein-1 (PD-1) under clinical...” NCT05366829 ↗ “A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage...” NCT04005716 ↗ “in combination with tislelizumab (BGB-A317) in participants with advanced or metastatic immune-sensitive solid tumors.” NCT06487858 ↗ “For patients with MSI-H/dMMR, consolidation immunotherapy of Tislelizumab (BGB-A317) will be assigned.” NCT04443543 ↗ “Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)” NCT04542369 ↗ “Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)” NCT07109401 ↗ “Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody” NCT03736889 ↗ “Tislelizumab (BGB-A317) with chemoradiotherapy” NCT06430658 ↗ “Tislelizumab (BGB A317, Anti-PD1 Antibody)” NCT05582265 ↗ “tislelizumab (also known as BGB-A317)” NCT06585488 ↗ “PD-1 antibody，Tislelizumab (BGB-A317)” NCT04815408 ↗ “Tislelizumab (BGB-A317)” NCT05547321 ↗ “Tislelizumab (BGB-A317)” NCT06829355 ↗ |
| Known as | Tileilizhu Dankang Zhusheye | “Tislelizumab (®;; Tileilizhu Dankang Zhusheye) is an anti-human programmed death receptor-1 (PD-1) monoclonal IgG4 antibody that is being developed by BeiGene as an...” PMID 32185681 ↗ Apr 2020 |
| Known as | Tirelizumab | “Tirelizumab,has been approved for the failure treatment of platinum-containing chemotherapy with high PD-L1 expression included locally advanced or metastatic Urothelial...” NCT04562311 ↗ |
| Known as | Tislelizumab (Tevimbra) | “Tislelizumab (Tevimbra)” NCT06520683 ↗ |
| Known as | Tislelizumab injection | “Tislelizumab Injection: 600 mg (initial dose) - 300 mg (subsequent doses), subcutaneously (SC), every 3 weeks (Q3W), for a total of 18 doses (1 year).” NCT06883552 ↗2“Tislelizumab injection is a humanized recombinant anti-PD-1 monoclonal antibody.” NCT06897579 ↗ “Tislelizumab injection” NCT05809336 ↗ |
| Known as | Tislelizumab-jsgr | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06725498 ↗ |
| Known as | tislezumab | “tislezumab (anti-PD-1 monoclonal antibody)” NCT06966154 ↗ |
| Action | Inhibit | “the Anti-PD-1 Monoclonal Antibody BGB-A317” NCT02407990 ↗ |
| Modality | Monoclonal antibody | “Tislelizumab, an investigational monoclonal antibody with high affinity and binding specificity for PD-1” PMID 32540858 ↗ Jun 2020 |
| Route | Intravenous | “patients (aged ≥18 years) enrolled in phase IA received intravenous tislelizumab 0.5, 2, 5 or 10 mg/kg every 2 weeks” PMID 32540858 ↗ Jun 2020 |
| Target | PDCD1 | “humanised anti-PD-1 monoclonal antibody” PMID 31378459 ↗ Aug 2019 |